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Respiratory syncytial virus (RSV) and influenza are among the most important causes 
of severe respiratory disease worldwide. Despite the clinical need, barriers to devel-
oping reliably effective vaccines against these viruses have remained firmly in place for 
decades. Overcoming these hurdles requires better understanding of human immunity 
and the strategies by which these pathogens evade it. Although superficially similar, the 
virology and host response to RSV and influenza are strikingly distinct. Influenza induces 
robust strain-specific immunity following natural infection, although protection by current 
vaccines is short-lived. In contrast, even strain-specific protection is incomplete after RSV 
and there are currently no licensed RSV vaccines. Although animal models have been 
critical for developing a fundamental understanding of antiviral immunity, extrapolating 
to human disease has been problematic. It is only with recent translational advances 
(such as controlled human infection models and high-dimensional technologies) that the 
mechanisms responsible for differences in protection against RSV compared to influenza 
have begun to be elucidated in the human context. Influenza infection elicits high-affinity 
IgA in the respiratory tract and virus-specific IgG, which correlates with protection. Long-
lived influenza-specific T cells have also been shown to ameliorate disease. This robust 
immunity promotes rapid emergence of antigenic variants leading to immune escape. 
RSV differs markedly, as reinfection with similar strains occurs despite natural infection 
inducing high levels of antibody against conserved antigens. The immunomodulatory 
mechanisms of RSV are thus highly effective in inhibiting long-term protection, with 
disturbance of type I interferon signaling, antigen presentation and chemokine-induced 
inflammation possibly all contributing. These lead to widespread effects on adaptive 
immunity with impaired B cell memory and reduced T cell generation and functionality. 
Here, we discuss the differences in clinical outcome and immune response following 
influenza and RSV. Specifically, we focus on differences in their recognition by innate 
immunity; the strategies used by each virus to evade these early immune responses; and 
effects across the innate-adaptive interface that may prevent long-lived memory genera-
tion. Thus, by comparing these globally important pathogens, we highlight mechanisms 
by which optimal antiviral immunity may be better induced and discuss the potential for 
these insights to inform novel vaccines.
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FiGuRe 1 | Schematic representation of comparative age distribution of 
respiratory syncytial virus (RSV), 2009 pandemic influenza and seasonal 
influenza mortality. RSV is a leading viral cause of infant death (8), with 
maternal antibodies offering temporally constrained protection to neonates 
against seasonal flu and RSV. This is limited in the case of novel pandemic 
influenza strains not previously encountered by the maternal immune system. 
Young adults are disproportionately affected by pandemic influenza strains, 
relative to seasonal influenza and RSV. Pandemic and seasonal influenza, as 
well as RSV all cause dramatic mortality in elderly individuals, reflecting the 
age-related decline of immune function in this population (8, 19).
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iNTRODuCTiON
Acute respiratory tract infection is a leading cause of morbid-
ity and mortality worldwide, 2.7 million deaths having been 
attributed to lower respiratory tract infections (LRTI) in 2013 
(1). Recent mortality statistics for England and Wales indicate 
that influenza and pneumonia were among the principal causes of 
death among both under 4 year olds and adults aged over 80 years 
(2), while in the US, pneumonia is known to be a predominant 
cause of hospitalization among pediatric and elderly populations, 
accounting for 36 hospital stays per 10,000 people (3). The causes 
of both upper and lower respiratory tract illnesses can frequently 
be traced to viral infections. A recent analysis of community-
acquired childhood pneumonia in the US found that two thirds 
of patients with a detectable pathogen were infected with one or 
more viruses, of which the most common was respiratory syncy-
tial virus (RSV) (4). This is consistent with global mortality data, 
which indicates that two of the most important causes of pneu-
monia in under 5 years olds are RSV and influenza (1). During the 
first 2 years of life, all children will have been infected at least once 
with RSV, with approximately two thirds infected by the end of 
their first year; in the UK this translates to a peak risk of hospital 
admission at approximately 1 month of age (5). With increasing 
age, subsequent RSV episodes decrease in severity, with a mild-
to-moderate upper respiratory tract infection (URTI) in healthy 
adults. However, in elderly patients RSV once again becomes a 
cause of severe disease (6). Unlike RSV, influenza shows a less 
dramatic bias toward pediatric infections, and the majority of 
seasonal influenza-related deaths occur amongst elderly patients 
(7–9), although in a USA study, Thompson et  al. found that 
rates of influenza-related hospitalization among infants and 
young children were on a par with those in the over-65s (8). This 
indicates that each year both pathogens represent an enormous 
disease burden in vulnerable population groups.
Influenza and RSV both circulate seasonally, with annual 
outbreaks in temperate regions occurring during winter months, 
although in tropical climates the seasonality is less distinct 
and peaks of infection occur year round (10). Both pathogens, 
which are responsible for recurrent infections throughout life, 
are enveloped single-stranded negative-sense RNA viruses. 
Influenza belongs to the Orthomyxoviridae family, and unlike 
RSV, which belongs to the Paramyxoviridae family, the genomes 
of the influenza genus are divided into segments. This segmented 
nature aids the emergence of variant viruses through antigenic 
shift (by genome segment reassortment), which in combination 
with antigenic drift (by accumulated point mutation), has led 
to enormous genetic diversity. Naturally occurring infection 
by influenza viruses is known to induce long-lasting protective 
immunity, although this is strain-specific. Recurrent infections 
therefore occur due to the antigenic variation seen in circulating 
strains over time. In contrast, reinfection with antigenically simi-
lar strains of RSV occurs frequently throughout life, especially in 
children and the elderly, indicating that the immunity induced 
by natural infection provides little long-term protection against 
reinfection (11). The natural histories of these two viruses are a 
consequence of the divergent immune sequelae that they pro-
voke, but the lack of persistently protective immunity following 
natural infection in each case can be seen as two sides of the same 
coin. The continued lack of a universal, effective vaccine against 
either virus means that both continue to cause huge burdens of 
mortality and morbidity across the globe.
CLiNiCAL, ePiDeMiOLOGiCAL, AND 
viROLOGiCAL FeATuReS OF RSv
Respiratory syncytial virus causes a spectrum of illness, which 
ranges from mild URTIs, or otitis media, to severe LRTIs, encom-
passing bronchiolitis. Bronchiolitis is associated with the infiltra-
tion of inflammatory cells into the airways, over-production of 
mucus, and edema of the respiratory tract (12). This leads to a 
progressive narrowing of the airways with increased airflow 
obstruction, causing tachypnea and hypoxia. The characteristic 
airway inflammation and epithelial necrosis associated with 
RSV-induced bronchiolitis has also been implicated in long-term 
impairment of lung function, as RSV infection during childhood 
is believed to be an important risk factor for the development 
of asthma and allergic wheeze during later life (13, 14). Indeed, 
Blanken et  al. have shown that treatment with the anti-RSV 
monoclonal antibody (mAb) palivizimab, reduces postviral 
wheeze at 1 year of age (15). An estimated global burden of 33.1 
million acute respiratory tract infections, resulting in 3.2 million 
hospital admissions in under 5  year olds, have been attributed 
to RSV (16). Approximately one third of deaths resulting from 
acute lower respiratory infection in the first year of life can be 
ascribed to RSV, with between 94,600 and 149,400 childhood 
deaths related to RSV every year (17, 18). However, with limita-
tions in healthcare provision in low and middle income countries, 
accurate epidemiological assessment in many regions is difficult 
due to inconsistent diagnostics and under-reporting of cases. In 
addition to the pediatric disease burden, RSV also contributes 
to significant morbidity and mortality in the elderly, immuno-
compromised individuals, and those with pulmonary or cardiac 
comorbidities (see Figure 1) (6).
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The 15.2 kb genome of RSV consists of 10 genes coding for 11 
proteins, many of which have been targeted in attempts to induce 
pathogen-specific immunity. Eight of the proteins are internal and 
include the matrix (M) and two non-structural proteins (NS1 and 
NS2). Further internal proteins are all associated with the con-
struction of the nucleocapsid. These include the products of the 
M2 gene, which are two polypeptides resulting from overlapping 
open reading frames: a nucleocapsid-associated transcription 
factor (M2-1) and the associated polypeptide involved in genome 
replication (M2-2). The nucleoprotein (N) and phosphoprotein 
(P) together interact with the RNA-dependent polymerase (L) 
to form the nucleocapsid. The 3 remaining transmembrane 
proteins are found in the viral envelope: the small hydrophobic 
protein (SH) which enhances membrane permeability in host 
cells through ion channel formation (20); the highly glycosylated 
major attachment protein (G), which mediates viral attachment 
to the host cell; and the fusion protein (F), which mediates both 
virus-to-cell and cell-to-cell fusion. RSV is relatively antigenically 
stable compared to influenza and only the G protein undergoes 
extensive variation akin to hemagglutinin (HA) and neurami-
nidase (NA) found on the surface of influenza. This has led to 
the classification of circulating RSV strains into two different 
antigenic groups (A or B) based upon divergent sequences within 
the G protein ectodomain. Furthermore, in addition to its genetic 
diversity, the virus also expresses G protein in a secreted form, 
which may function as an antigenic decoy (21).
The F protein has presented an attractive target for rational 
vaccine design since the early days of RSV vaccine development. 
While both G and F proteins are immunogenic targets of the anti-
body response, F is the only one essential for cell entry and (unlike G) 
is highly conserved across all known RSV strains. However, the F 
protein presents an unusual target for the immune system, as the 
metastable prefusion conformation present in the virus rapidly 
undergoes a number of structural changes both spontaneously 
and following host cell binding that results in a secondary, more 
thermodynamically stable postfusion form (22–24). Both forms 
of this protein display epitopes but only three of the antigenic 
sites (I, II, and IV) found on the prefusion protein are preserved 
following conformational change. These have been defined by 
mAbs, with site I recognized by mAbs such as 2F, 44F, or 45F 
and site IV by mAb19 and 101F (25, 26). Site II is targeted by the 
humanized monoclonal IgG antibody, palivizumab, currently the 
only clinically approved RSV immunoprophylaxis in use. In high-
risk infants, monthly administration of palivizumab reduces RSV 
hospitalizations by at least 50%, showing that systemic IgG alone 
can confer protection against LRTI. However, the relatively mod-
est efficacy, high cost and requirement for repeated dosing pre-
cludes its use in resource-constrained settings. Furthermore, all 
of the antibodies raised against these antigenic sites show at best 
moderate neutralizing activity and postfusion F protein-based 
vaccines have so far failed to demonstrate efficacy in clinical trials 
(27, 28). In contrast, the most potent RSV neutralizing antibodies 
are raised against the site Ø epitope, which is found exclusively 
in the pre-fusion conformation of the protein, the structure of 
which was only recently elucidated. The mAbs D25, AM22, and 
5C4, which target this site, have a neutralizing potency up to 
100-fold greater than palivizumab, giving rise to the possibility 
of more effective antibody-mediated protection if site Ø can be 
preferentially induced (24, 29).
While vaccination remains the most cost-effective health 
intervention for infectious diseases, there are currently no effec-
tive vaccines available against RSV. This underdeveloped state of 
vaccine development is due in part to the unenviable position 
that an early RSV vaccine candidate has in the history of vac-
cines. During the late 1960s, a clinical trial involving vaccination 
of children with an alum-precipitated formalin-inactivated RSV 
vaccine preparation (FI-RSV) led to exacerbated disease upon 
subsequent natural infection with live RSV. Although almost 
half (43%) of the infants receiving the vaccine displayed at least a 
fourfold rise in serum neutralizing antibody titer and almost all 
(91%) had at least a fourfold rise in complement fixing antibody, 
80% of vaccinees required hospitalization for pneumonia and 
bronchiolitis on subsequent RSV exposure, resulting in two 
fatalities (30, 31). Considerable research effort over the decades 
since has sought to determine the mechanisms responsible 
for this immunopotentiation or “vaccine-enhanced disease.” 
Subsequent studies have suggested that formalin-inactivation led 
to the deformation of B cell epitopes, which may have promoted 
the development of non-neutralizing antibodies (32). This in 
combination with CD4+ T cell responses biased toward produc-
tion of Th2-associated interleukins (IL) (IL-4, IL-5, and IL-13), 
may have exaggerated immunopathology upon later infection 
to RSV (33). There is also recent evidence that deficient toll-like 
receptor (TLR) stimulation resulting in a lack of antibody affinity 
maturation may have played a role (34).
The state of RSV vaccine development has drastically improved 
over the last decade in view of increased understanding of disease 
burden and antigenic targets. Almost 50 vaccine and mAb prod-
ucts are in development, of which several are currently in clinical 
trials (35, 36). However, the recent failure of a recombinant 
F protein nanoparticle vaccine candidate in a phase III trial of 
elderly adults despite showing immunogenicity in earlier clinical 
trials (37–40), demonstrates that there is still an urgent need to 
improve our understanding of immune correlates of protection 
for this pathogen.
CLiNiCAL, ePiDeMiOLOGiCAL, AND 
viROLOGiCAL FeATuReS OF iNFLueNZA
Acute respiratory infections with seasonal influenza cause an 
estimated 3–5 million cases of severe illness and 250,000–500,000 
deaths globally each year (17, 41), with an accumulated cost in the 
USA alone of ~$87 billion per annum (42). In addition to this ever 
present threat to public health, there is the constant possibility 
that a novel virus with a high case-fatality rate may emerge and 
prove capable of initiating a pandemic. Over the past 100 years 
there have been four such pandemics: the H1N1 Spanish flu 
in 1918 which was responsible for 50–100 million deaths; the 
H2N2 outbreak in 1957 which caused 100,000 deaths; the H3N2 
outbreak in 1968 which caused 700,000 deaths; and the recent 
H1N1 pandemic in 2009 which claimed over 15,000 lives (43). 
Although large variations have been seen in the excess mortality 
caused by successive pandemic influenza strains, these appear to 
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disproportionately affect young adults relative to seasonal influ-
enza and RSV (Figure 1), these deaths have been linked to an 
influenza initiated “cytokine storm” and a susceptibility to lethal 
secondary bacterial pneumonia (44, 45). Influenza viruses which 
have their origins within the avian viral reservoir have accounted 
disproportionately for many of these deaths, and continue to 
represent an emerging threat to human health as the progenitors 
of the next influenza pandemic. Currently, two strains of highly 
pathogenic avian influenza are circulating in birds and causing 
sporadic outbreaks in humans (H7N9 in South East Asia, and the 
panzootic H5N1), both of which have pandemic potential.
As with RSV, influenza viruses enter hosts either intranasally 
or less commonly via the eye, following exposure to infected 
secretions. Influenza infection is then initiated within the airway 
by the attachment of HA to sialic acid receptors on the surface of 
the host epithelium. While RSV is uniquely adapted to human 
cells, with attachment thought to be mediated by the chemokine 
receptor CX3CR1 (46), HA may be adapted to a number of 
species and specificity is thought to be a critical factor in host 
tropism. Avian influenza HA preferentially binds to α(2,3)-sialic 
acid linkages, while influenza viruses circulating in humans pos-
sess HA subtypes that recognize and attach to the α(2,6)-sialic 
acid linkages more commonly expressed in the human respira-
tory tract. It is possible to modify this binding specificity through 
the mutation of a single amino acid within the receptor binding 
domain, increasing the likelihood of the virus acquiring the capa-
bility to infect a new host species. This is of particular concern in 
pigs and certain birds, such as turkeys, which have both α-2,3 and 
α-2,6 linkages, and are thus capable of acting as mixing vessels to 
generate reassortant viruses (47).
Influenza viruses are divided into A, B, and C types. Influenza 
A viruses, which are the pathogens responsible for the major-
ity of seasonal and all pandemic influenza infections, infect 
a range of mammals and birds, while types B and C typically 
infect humans. They all possess segmented genomes: influenza 
A and B contain eight RNA segments and influenza C seven. 
The influenza A genome encodes 11 core and accessory viral 
proteins. A further two proteins (negative sense protein and the 
N-terminal truncated variant N40) may have a role in late-stage 
infection but as yet their functions remain unclear (48, 49). In 
common with RSV there are two non-structural proteins (NS1 
and NS2) and influenza also possesses two matrix proteins; M1 
is found within the lipid bilayer surrounding the virus core and 
M2 is a transmembrane ion channel. The internal core of the 
virus is a ribonucleprotein RNA-dependent polymerase complex 
composed of a nucleoprotein (NP), polymerase acidic (PA), and 
two polymerase basic subunits (PB1 and PB2) along with an 
alternatively transcribed proapoptotic peptide, PB1-F2. Influenza 
viruses are divided into subtypes based on sequence variations in 
their main surface glycoproteins: HA (which is divided into two 
subunits, HA1 and HA2) and NA. These are involved in host cell 
attachment and host cell egress, respectively. Thus far, 18 different 
HAs and 11 NAs have been defined.
In common with RSV, the surface glycoproteins of influ-
enza are the major targets of the protective humoral response. 
However, unlike RSV, both proteins are apt to vary greatly as a 
result of antigenic drift and shift (50). In comparison, the genes 
encoding the internal virus proteins such as the M gene, are 
highly conserved between influenza A viruses (50). While it is 
possible to generate effective vaccines which offer protective 
immunity against circulating strains, the changing nature of both 
seasonal and pandemic viruses means that individuals need to 
be vaccinated repeatedly as mutations are gathered and it is not 
possible to produce a tailored vaccine quickly and affordably in 
the quantities required to respond to a novel pandemic virus.
iNNATe iMMuNiTY FOLLOwiNG 
ReSPiRATORY viRuS iNFeCTiON
intrinsic and immediate Barriers to 
infection in the Respiratory Tract
During the initial stages of respiratory virus infection the naso- 
and oro-pharynx are the primary sites of exposure. These areas 
are covered by a thick mucus layer, which protects the epithelial 
cells. However, mucin macromolecules and sialic acid compounds 
found within this mucus throughout the respiratory tract can be 
cleaved by influenza NA, leaving HA free to bind to cell-surface 
sialic acid residues and initiate viral entry (51). The action of NA 
has been shown to be crucial in this regard, as oseltamivir blocks 
influenza infection of mucus-producing human bronchial epithe-
lial cells (52). RSV lacks this sialic-acid cleaving capacity and host 
cells respond to infection by expression of mucins, the specific 
mucin protein MUC5AC is elevated in A549 human alveolar 
epithelial (53) and bronchial epithelial cells (54). MUC5AC is also 
linked to the innate immune response, being elevated through 
chemokine (C-X-C motif) receptor CXCR2 signaling in a mouse 
model of RSV infection (55). Although the exact extent to which 
mucus upregulation alters infection risk is unclear in humans, the 
protective effects of MUC5AC overexpression during influenza 
infection of mouse models (56) suggest that this often overlooked 
first line of defense plays an important role in warding off both 
respiratory viruses. Within mucus, other immediate mechanisms 
including cationic host defense peptides such as cathelicidin have 
also been shown to play a role in disrupting respiratory viruses 
at the point of virus encounter (57, 58). Both influenza and RSV 
envelopes are directly damaged by cathelicidin, which represents 
one of a number of ancient defense mechanisms that may act 
immediately to prevent entry of virus into nasal cells. Emerging 
evidence suggests that respiratory viruses may harness posttrans-
lational modification of these defenses to abrogate their function. 
Indeed, it remains to be seen whether these early barrier mecha-
nisms can be manipulated for the purposes of prophylaxis and 
for the time being the focus is therefore on the innate-adaptive 
immune axis for vaccine development.
The Role of Pattern Recognition 
Receptors in Respiratory virus infection
Airway epithelial cells, neutrophils, alveolar macrophages 
(AMs) and dendritic cells (DCs), and members of the innate 
lymphoid cell (ILC) family resident in the respiratory tract make 
up the first line of innate immune cellular defense. These cells 
are capable of sensing viral RNA, the predominant pathogen-
associated molecular pattern (PAMP) of influenza and RSV, 
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as well as cell-generated danger-associated molecular patterns 
(DAMPs), through several families of highly conserved pattern 
recognition receptors (PRRs). Innate recognition through PRRs 
has a profound impact on the entire immune response and it is 
increasingly obvious that pathogens interfere with these pathways 
to modulate both short and long-term immunity.
In Figure  2, we highlight the mechanisms involved in the 
induction of innate and adaptive immunity to influenza and RSV, 
and how the disparity in protection may be related to the manner 
in which these pathogens engage PRRs.
The three key families of PRRs involved in sensing viral 
infection are TLRs, retinoic acid inducible gene-I (RIG-I), and 
nucleotide-binding oligomerization domain (NOD)-like recep-
tors (NLRs). These function as critical components of the initial 
innate immune response, governing the release of cytokines 
including the type I interferons α and β (IFN α/β). This was 
recently shown by Forero et  al., who found by transcriptomic 
analysis of human nasal epithelial cell cultures that the innate 
response to viral infections such as influenza is driven by type 
I and III IFN (59). This was also associated with induction of 
the chemokine (C-X-C motif) ligands for CXCR3; CXCL9, 
CXCL10, and CXCL11, indicating a coordinating role for the 
early innate epithelial response in the recruitment of monocytes 
and generation of effector and memory CD8+ T cells (59). Large 
scale genetic studies have also demonstrated that susceptibility 
to RSV-induced bronchiolitis are associated with polymorphisms 
in innate immune genes (60, 61). However, the contribution of 
individual genetics to innate immune responses (both positive 
and negative) is yet to be clearly delineated. A recent study of 
common single-nucleotide polymorphisms in RLRs and IL-4 
signaling genes have showed no link to susceptibility to severe 
RSV infection and there remains controversy in the field (62). 
Nevertheless, it is clear that innate recognition of PAMPs and 
DAMPs triggers the induction of the antiviral immune response 
and might reasonably be a point at which viruses attempt to evade 
detection.
Intracellular Toll-Like Receptors Recognizing  
RSV and Influenza
The intracellular receptors TLR3, TLR7, TLR8, and TLR9 all play 
a role in sensing viral infection. TLR3 is an important activa-
tor of type I IFNs; interacting with the toll/IL-1 receptor (TIR) 
domain-containing adaptor protein inducing IFN beta (TRIF) 
to activate serine-threonine kinases IκKε and TANK-binding 
kinase 1 (TBK1), phosphorylating the IFN regulatory factor 3 
(IRF3) which induces the expression of IFNβ. TLR3 recognizes 
double-stranded RNA (dsRNA), a potent DAMP, which may be 
released from virus-infected phagocytosed cells (63). Within 
human respiratory epithelial cells, which constitutively express 
TLR3, downstream proinflammatory cytokine production may 
be protective, but can also lead to pathology (64). This is borne 
out by animal studies which indicate that, despite an elevated viral 
load, tlr3−/− mice show decreased infiltration of inflammatory 
cells into the lungs and increased survival rates following lethal 
influenza challenge (65). Conversely, in a tlr3−/− mouse model of 
RSV infection, alteration of the immune environment leads to 
increased IL-13 and an associated overproduction of mucus (66). 
In this context, it is interesting that both Influenza A and RSV 
infection lead to upregulated expression of TLR3 in pulmonary 
epithelial cells but that this may result in different outcomes 
(67, 68). Adding further to this complexity, influenza and RSV 
infection can promote increased production of CXCL8/IL-8 
upon subsequent re-stimulation with TLR3 ligands, suggesting 
that previous virus exposure can induce “trained” immunity that 
may be both beneficial and harmful to the host (67, 68). However, 
despite the importance of TLR3 in the early immune response, 
tlr3−/− mice have been found to generate normal humoral and 
T cell responses to sublethal influenza infection (69), which sug-
gests that, at least in the case of influenza, TLR3 stimulation is not 
essential for the induction of adaptive immunity.
This redundancy can also be seen in the activation of TLR7; 
neither activation of TLR3 nor TLR7 alone appear capable of 
stimulating IFN-mediated antiviral defense during infection. 
TLR7 is highly expressed in plasmacytoid dendritic cells (pDCs), 
being capable of detecting the single stranded RNA (ssRNA) 
present in viruses which are taken up into the endosome. It 
interacts with the adaptor protein, myeloid differentiation factor 
88 (MyD88) (70, 71) leading to the activation of nuclear factor-κB 
(NF-κB) and IRF7, transcription factors that are responsible for 
stimulating the expression of proinflammatory cytokines and 
type I IFNs (72–74). Murine DCs deficient in either TLR7 or 
MyD88 show reduced levels of IFNα induction following influ-
enza virus infection (70, 71). This is in accordance with animal 
models of infection, which found that naive myd88−/− tlr3−/− and 
tlr7−/− mice were more susceptible to influenza virus infection, 
demonstrating that MyD88 signaling is important in resisting 
primary challenge (75). Although MyD88 signaling was essential 
for optimal induction of Th1 cells, with Th2 skewing in MyD88 
and TLR7 deficient mice (75, 76), Seo et  al. found that virus-
specific IgG and IgA titers were unaffected and that TLR deficient 
mice were protected against secondary lethal challenge (75). 
Other mouse models have found that, despite elevated hemag-
glutinin inhibition (HI) titers and protective immunity against 
rechallenge, tlr7−/− myd88−/− mice demonstrate impaired B  cell 
responses (77). Indeed, TLR7 stimulation has proven critical for 
isotype class switching in influenza infection (69) and augments 
antibody secreting cell (ASC) differentiation (78). Taken together 
this evidence indicates that TLR7 plays an important role in the 
primary response to influenza, but is not essential to the develop-
ment of a memory response. In an interesting caveat to this, TLR7 
signaling appears to be crucial to the development of protective 
HI antibodies targeting the pandemic H1N1 (pH1N1) 2009 
split vaccine (77), suggesting that the context (infection versus 
vaccination) in which PRRs recognize viral RNA directs their 
relative importance. In RSV, TLR7 appears to have an important 
role in promoting a non-pathogenic T cell response to infection. 
Engagement of this ligand elicits the IL-12 and type I IFN produc-
tion required for Th1-type responses, and may skew immunity 
away from a harmful Th2 response (66, 70, 71). The absence of 
TLR7 expression in tlr7−/− mice does not affect the clearance 
of RSV from infected animals, but does promote the release of 
mucogenic cytokines IL-4, IL-13, and IL-17, and preferentially 
activating IL-23, which is associated with an immunopathogenic 
Th17 response to RSV in the lungs (79). TLR7 has also proven 
FiGuRe 2 | Continued
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to have an important role in the humoral response to viruses, 
inducing B cells to release antigen specific antibodies following 
sublethal doses of influenza virus (69, 77, 80).
In common with TLR7, the remaining “viral-sensing” intra-
cellular receptors, TLR8 and 9, both initiate proinflammatory 
cytokine release through the MyD88 signaling pathway. TLR8, 
which is stimulated by the presence of ssRNA in monocytes and 
macrophages, induces production of IL-12, proinflammatory 
IL-6, tumor necrosis factor (TNF), chemokine (C-C motif) 
ligand/monocyte chemoattractant protein CCL2/MCP-1, and 
CXCL8/IL-8 but not IFNα (81–83). TLR9, which recognizes 
unmethylated CpG repeats within DCs, is a potent inducer 
of proinflammatory and Th1 responses, and upregulates the 
costimulatory molecules CD80/86. The action of these receptors 
plays a role in innate immunity and signaling, the impact of 
which upon viral replication and dissemination has only recently 
begun to be investigated. During influenza infection increased 
TLR7/8/9 expression is known to correlate with elevated produc-
tion of Th1-related cytokines IFN-γ, CXCL10/IFN-γ induced 
protein 10 and CXCL9/monokine induced by IFN-γ (MIG). 
The administration of CpG as a TLR9 ligand during exposure to 
purified RSV F or G proteins or killed bovine RSV (BRSV) also 
results in Th1-associated immune responses (84–88). Mucosal 
administration of a TLR9 ligand CpG oligodeoxynucleotides/
L18-muramyl dipeptide (CpG ODN/L18-MDP) with inactivated 
RSV viral particles potently activates NF-κB, shifting cellular 
immune responses toward a dominant IFN-γ-producing Th1-
type response (89). Furthermore, mucosal immunization of 
BALB/c mice with inactivated RSV and TLR9 ligands induce 
local IgA responses and Th1-associated IgG2a high-affinity 
FiGuRe 2 | Comparative immunity in respiratory syncytial virus (RSV) and influenza. Within the mucosal surfaces of the lung the host immune response to each 
virus feature intersecting and non-overlapping traits. (A) Influenza and RSV establish infection in the lung epithelial cells, initiating the release of type 1 interferons 
(IFNs) which act in a feedback loop along with release of proinflammatory cytokines such as interleukin (IL)-1β and IL-18, and upregulation of IFN-stimulated genes 
(ISGs) to promote an inflammatory environment. This inflammatory milieu, which in influenza recruits conventional dendritic cells (cDCs) and plasmacytoid DCs 
(pDCs) as the primary type 1 IFN producing antigen-presenting cells (APCs), promotes optimal signaling and memory generation. This includes polyfunctional CD8+ 
and Th1 T cells, and immunocompetent IgG+ and IgA+ ASCs and memory B cells (MBCs). Following viral clearance T cells remain in the lung as T resident memory 
(Trm) and MBCs and T cells traffic into the systemic compartment. RSV infection of the lung follows a broadly similar pattern, although the primary type 1 IFN 
producing APCs are alveolar macrophage (AM) and cDCs. The lower levels of type 1 IFN produced during infection impact the generation of memory responses with 
poorly functional T cells, skewing toward Th2/Th17 generation in early life and a profound defect in the induction of an IgA+ MBC subset. As the influenza virus 
establishes infection within a lung epithelial cell (B) it enters the endosome and following viral uncoating it triggers TLR3 signaling with double-stranded RNA 
(dsRNA) and TLR 7/8/9 with single-stranded RNA (ssRNA), in addition retinoic acid inducible gene-I (RIG-I) and the inflammasome are stimulated by contact with 
dsRNA and ssRNA, respectively. These signaling pathways individually stimulate nuclear factor-κB (NF-κB), IRFs and upregulate ISGs and the production of type 1 
IFNs. These mediators are released by the cell and recognized by IFNα receptor (IFNAR), leading to positive feedback, which also stimulates the sequestration of 
virus by IFN-induced transmembrane protein (IFITM), preventing viral spread. Influenza acts to mitigate the actions of the pattern recognition receptors (PRRs), 
especially RIG-I and the inflammasome through NS1-mediated inhibition, while hemagglutinin (HA) has recently been found to trigger ubiquitination of IFNα receptor 
(IFNAR), downregulating IFNAR1 expression. In the case of RSV infection within a lung epithelial cell (C) the action of the intracellular PRRs is augmented by the 
engagement of the extracellular TLRs 4/2/6. RSV strategically targets signaling pathways at multiple points, most notably the action of G protein upon TLR7/8/9 and 
TLRs 4/2/6, and NS1 upon a number of pathways, particularly STAT signaling.
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antibody responses (89). It is notable that the engagement of 
TLR9-induced signaling pathways during FI-RSV immunization 
is even capable of ameliorating vaccine-enhanced disease (90). 
TLR9 polymorphisms have also been associated with the risk of 
developing RSV linked post-bronchiolitis wheeze (91). Thus, it 
is likely that appropriate TLR-signaling will be required for an 
effective early vaccine-induced response.
Extracellular TLRs in RSV
The extracellular receptors TLR2, TLR4, and TLR6 are com-
monly recognized as bacterial sensors, given that they recognize 
lipoproteins, peptidoglycans and bacterial cell-surface lipopoly-
saccharides, respectively. Nevertheless, these TLRs, which signal 
through the MyD88 pathway, have been found to play an impor-
tant role in governing the immune response to RSV. The release of 
NF-κB-related proinflammatory cytokines from airway epithelial 
cells is the primary mode of action for TLR2 and TLR6, which do 
not contribute to the production of type I IFN (92). Engagement 
of both TLR2 and TLR6 has an effect upon cytokine and 
chemokine production during RSV infection, and increased viral 
loads have been observed in mice deficient for these receptors, 
with impaired neutrophil migration and DC activation in tlr2−/− 
mice (93). The release of proinflammatory cytokines in response 
to heat-inactivated RSV exposure can also be inhibited by TLR2 
blocking antibodies (94). The pathogenic effect is compounded 
in MyD88−/− mice, as multiple TLR pathways (TLR2, TLR4, and 
TLR7) are abrogated, leading to increased Th2 cytokine release, 
mucus hypersecretion, and eosinophilia (66).
However, it is primarily TLR4 which has drawn attention 
for its interaction with F protein during the early stages of RSV 
infection (93). Indeed, due to its extracellular nature it is difficult 
to escape the idea that TLR4 may be the first PRR activated dur-
ing RSV infection, providing an early innate activation signal 
sensing infection. TLR4 activation has been associated with RSV 
clearance in several studies (95–98) and severe RSV disease in 
infants has been linked to TLR4 polymorphisms (99). In the 
cotton rat model, inclusion of the adjuvant monophosphoryl 
lipid A (MPL), which is a partial TLR4 agonist, in an FI-RSV 
formulation ameliorated the lung pathology associated with 
vaccine-enhanced disease. This was associated with a reduction 
in the levels of Th1- and Th2-type cytokines and chemokines nor-
mally released following RSV challenge (86, 100). This suggests 
that while TLR4 engagement is important in mounting an early 
antiviral response to RSV, it is also capable of provoking complex 
dysregulation of multiple cytokines. It is therefore not surpris-
ing that the RSV G protein may have evolved to target TLR2, 
4, and 9 expression in human monocytes, suppressing innate 
immune responses through multiple downstream mechanisms 
(101, 102). However, conflicting studies have also suggested 
that depletion of TLR4 does not impact RSV clearance, nor its 
infiltration of pulmonary inflammatory cells (103). TLR4 has also 
been linked to the induction of acute lung injury (ALI) during 
influenza infection, with exposure to influenza derived antigens 
inducing nicotinamide adenine dinucleotide phosphate oxidase-
dependent production of reactive oxygen species which generate 
oxidized host phospholipids. These were found to include the oxi-
dized 1-palmitoyl-2-arachidonoyl-phosphaticylcholine, a potent 
activator of the TLR4-TRIF signaling pathway, which triggers 
production of proinflammatory cytokines, such as IL-6, by pul-
monary macrophages, leading to lung injury (104). Abrogation of 
TLR4 expression, either through administration of a therapeutic 
antagonist or use of tlr4−/− murine strains, provided protection 
against virally induced lung injury in mouse models of influenza 
infection (104–106). Nevertheless, it is likely that, unlike RSV 
which is recognized by both intracellular and extracellular TLRs, 
pathogen sensing of influenza is predominantly mediated by 
intracellular TLRs.
Intracellular Sensing by RIG-I-Like Receptors  
and Innate IFNs
The RIG-I like receptor (RLR) family represent an important 
additional viral recognition pathway which governs type I IFN 
production in infected cells. Within the cytosol of the host cell a 
5′ triphosphate dsRNA “panhandle” is formed by the conserved 
5′ and 3′ end sequences of replicating viral ssRNA. This is detected 
by one of the RLR helicases, RIG-I (107, 108). RIG-I and mela-
noma differentiation-associated protein 5 (MDA5) (triggered by 
longer dsRNAs) both possess caspase activation and recruitment 
(CARD) domains. MDA5 predominantly senses positive-strand 
RNA, but can also be triggered by certain negative-strand RNA 
viruses, such as members of the Paramyxoviridae family (109) 
and influenza viruses (110). The CARD domains are lacked by 
the final RLR family member, the laboratory of genetics and 
physiology 2 (LGP2) molecule. The exact role of LGP2 in antiviral 
signaling has not yet been fully elucidated, as it has both negative 
and positive regulatory functions, depending upon the signaling 
context (111). These adaptor proteins interact with the mito-
chondrial antiviral-signaling protein (MAVS) or IFN-β promoter 
stimulator 1 (IPS-1) molecules and initiate signaling transduc-
tion cascades that leads to activation of downstream NF-κB and 
IRF3 pathways (112, 113). This stimulates the induction of type I 
IFNs. In the case of IFNβ this leads to transcriptional activation 
of numerous IFN-stimulated genes (ISGs), the most important 
of which are the IFN-induced transmembrane protein (IFITM) 
family, the myxovirus resistance proteins (Mx), the serine/threo-
nine kinase protein kinase R (PKR), and the 2′–5′-oligoadenylate 
synthetase/RNase L system. The IFITM family member IFITM3 
has recently been identified as an important receptor in antiviral 
response against influenza, as it blocks viral entry by impairing 
virus-host cell membrane fusion, impacting viral susceptibility 
(114, 115). Both IFITM3 and IFITM1 show a similar impact 
upon RSV activity, suppressing early viral entry, with IFITM3 in 
particular delaying the phosphorylation of IRF3 by sequestering 
RSV in vesicular compartments (116). The Mx family of large 
guanosine-5′-triphosphate hydrolase enzymes represents another 
important antiviral factor acting against RNA viruses. In human 
columnar epithelial cells, the Mx proteins interfere with nuclear 
transport of viral nucleocapsids to impair influenza transcription 
and replication (117, 118). The evolutionary pressure exerted by 
these proteins is capable of causing adaptive mutations in NP 
which have been observed in pandemic influenza A strains (119).
Given that it is widely conserved across vertebrates, the RLR 
family clearly plays an important role in sensing and responding 
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to viral infections. An instructive exception to this is demon-
strated by the lack of RIG-I receptors within chickens, which has 
been posited as an explanation for the increased susceptibility 
of chickens to avian influenza strains, compared to naturally 
resistant waterfowl such as ducks, which possess a fully func-
tional RIG-I signaling pathway (120, 121). Type I IFNs remain 
important in chicken antiviral immunity and recent research 
suggests that the role of sensing influenza infection is assumed 
by MDA5 in these animals (121). Indeed, animal models, which 
have long been used as surrogates for evaluating human influenza 
and RSV infection, show many such unique features, which can 
unfortunately complicate extrapolation of host and viral factors 
involved in the immune response to humans (122). This can be 
observed in the Mx family, as many of the inbred mouse strains 
used in research, such as C57BL/6 and BALB/c, carry defective 
genes for Mx1 and Mx2. This has led to a complex picture of 
MyD88-dependent immunity which long underestimated the 
role of pDCs in pulmonary defense (123, 124). Mice have been 
broadly employed to study host-genetic determinants and have 
helped to identify many host genetic candidates of the genetic 
host regions involved in antiviral protection (125, 126). However, 
these animals remain a poor model for respiratory virus trans-
mission, in contrast to which the ferret model is better suited for 
studying both the pathogenicity and transmissibility of human 
respiratory viruses (127), despite suffering from a lack of special-
ized reagents. It is only recently that physiologically relevant 
human challenge studies have allowed researchers to elucidate in 
detail the course of disease within immune compartments such as 
the lung (128, 129). Further systems biology analysis of mucosal 
tissues obtained during in vivo respiratory viral infection will be 
critical for better understanding of these sensors in humans.
Evasion of PRR Recognition and Signaling  
by RSV and Influenza
The importance of PRRs in the antiviral response and their likely 
early evolutionary emergence as mediators of protection mean 
that both RSV and influenza have evolved potent immunomodu-
latory mechanisms to overcome these pathways, often in a highly 
species-specific manner (130, 131). During early influenza infec-
tion this takes the form of concealing the dsRNA “panhandle” 
recognized by RIG-I through the action of the nucleocapsid 
polymerase complex (132). Avian adapted strains which have a 
reduced PB2-NP affinity are consequently sensed more effectively 
in cells possessing RIG-I (133). The RSV leader sequence per-
forms a similar function, utilizing the host cellular RNA-binding 
protein La to inhibit the early RIG-I binding and thus detection of 
RSV (134). The non-structural proteins derived from both viruses 
impact the innate immune signaling at multiple points, interact-
ing with the ubiquitin E3 ligases, Tripartite motif-containing 
protein 25 and Riplet, to prevent RIG-I ubiquitination (135, 136). 
Influenza NS1 prevents the activation of PKR and the nuclear 
translocation of transcription factors NF-κB and IRF3 to suppress 
type I IFN synthesis (131, 137–144). In addition, recent evidence 
has suggested that influenza HA also targets the positive feedback 
loop of IFN upregulation by interfering with the IFN receptor 
(145). Zhang et al. also found that RSV-derived NS1 specifically 
inhibits IFN-β production by decreasing RIG-I interaction with 
MAVS (116). The NS2 protein of RSV also inhibits RIG-I acti-
vation of IFN promoters by binding to the N-terminal CARD 
domains of RIG-I and inhibiting MAVS interactions (131). In 
addition, NS2 induces degradation of the signal transducer and 
activator of transcription 2 (STAT2) signaling pathways involved 
in MAVS activation (MAVS) (131, 146). RSV strains deficient in 
NS1 and NS2 expression show incomplete suppression of type 
I IFN production during human macrophage and epithelial cell 
infection, leading to a diminished ability to replicate in  vivo. 
Thus respiratory viruses rely to a great extent upon these immu-
nomodulatory proteins to evade the early antiviral response and 
establish infection. Whether these mechanisms are more potent 
in RSV than influenza and have a greater impact on downstream 
impairment of host immunity is difficult to test but they certainly 
contribute to an immediate failure to control RSV infection as 
well as probably the inability to elicit long-term protection.
Plasmacytoid DCs in RSV and Influenza
Another clue to the reasons for divergence in immunity against 
the two viruses can be found in the response of neonates and pre-
viously uninfected infants to their first encounter with RSV. Until 
recently, in both murine influenza and RSV, the infiltration of 
pDCs was thought to play the major role in type I IFN-dependent 
virus control (147, 148). In vitro, while pDCs from adults are 
capable of responding to cytosolic delivery of RSV-derived 
dsRNA in a RIG-I–dependent manner (149) by producing type 
I IFN independent of endosomal TLR activation and PKR (150), 
similar responses are profoundly impaired in neonates (151). In 
neonatal mice especially, the limited pDC function and associated 
type I IFN deficit contribute to Th2-skewed immunopathology in 
RSV infection (152). Marr et al. not only found that RSV-related 
IFN-α release is impaired in neonates, but also that peripheral 
blood cells from children aged between 12 months and 5 years 
show similarly reduced responsiveness to RSV and synthetic 
5′ppp-dsRNA RIG-I agonists (151). This is less clear in  vivo, 
where expression levels of MDA-5, RIG-I, TLR7 and TLR8 were 
all highly elevated in the respiratory tract of infants with bron-
chiolitis (153). This may have been partially confounded by other 
respiratory viruses being responsible for bronchiolitis in some of 
these infants, activating alternative pathways. Plasmacytoid DCs 
primarily sense ssRNA viruses, including influenza, through the 
endosomal TLR7/8 pathway (66, 101). In the case of RSV, endoso-
mal maturation and acidification is not required for viral fusion, 
which may lead to bypassing of the activation of such receptors 
entirely (154, 155). In contrast, exposure to a low endosomal 
pH is necessary for the conformational changes that trigger the 
release of influenza viral ribonucleoproteins from the M1 protein, 
and subsequent viral-endosomal fusion (156). A fusion pore is 
then formed, through which viral RNA exits the endosome to 
the cytosol and then on to the nucleus, where viral replication 
and mRNA transcription occurs (122, 156, 157). It is possible that 
pDC exploit this requirement to enter the acidified compartment 
by initiating proteolytic cleavage and TLR activation. Work in 
mice lacking asparagine endopeptidase suggests that peptidase-
dependent activation of TLR7 is essential for cross priming of 
CD8+ T  cells in influenza infection (70, 158). In comparison, 
10
Ascough et al. Comparing Human Immunity against Influenza and RSV
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 323
RSV not only evades recognition by pDC TLRs, but is capable of 
abolishing TLR7 and TLR9-dependent IFN-inducing pathways 
in pDC (150, 154). This difference in the routes taken by the two 
viruses through the host cells and therefore which PRRs are dif-
ferentially activated may represent a key divergence. Recent stud-
ies have suggested that, in vivo, the primary source of type 1 IFN is 
AMs and not pDCs (see below). It is unclear whether differences 
in mechanisms of viral entry play a role in this dichotomy.
NLRs and Inflammasome Activation by RSV
The cytosolic receptor NLR family consists of members NOD1, 
NOD2, and NACHT, LRR and PYD domains-containing protein 
3 (NALP3, also known as cryopyrin), which are capable of recog-
nizing PAMPs and contributing to the immune response in col-
laboration with membrane-bound TLRs (159). Conventionally 
these receptors are activated by molecules, such as muramyl 
dipeptide, which are produced during the degradation of bacterial 
peptidoglycan, inducing transcription of immune response genes 
through NF-κB and mitogen-activated protein kinase signaling 
pathways. Recent studies have indicated that NOD2 may play a 
role in sensing viral ssRNA, facilitating MAVS-dependent IRF3 
activation and type I IFN production in RSV infection (160). 
However, it is cryopyrin (encoded by the Nlrp3 gene), which has 
garnered attention for its antiviral activity via formation of the 
inflammasome, a caspase-1 activating molecular complex (161). 
Upon exposure to virally derived ssRNA the NALP inflamma-
some recruits ASC (apoptosis-associated speck-like protein 
containing a CARD) and procaspase-1, which is then activated 
by autocatalytic cleavage to caspase-1. This catalyzes proteolytic 
processing of pro-IL-1β, pro-IL-18, and pro-IL-33 into active 
proinflammatory cytokines.
In RSV infection, the SH protein accumulates in lipid rafts of 
the Golgi apparatus, acting as a viroporin to enhance membrane 
permeability and promote the entry of ions and small molecules 
into host cells. This enhances ion-sensitive transcriptional factors 
promoting viral replication and has also been implicated in NLRP3 
inflammasome activation (162, 163). Depletion of SH leads to 
defective NLRP3/ASC inflammasome activation and IL-1β secre-
tion (163). The M2 protein of influenza also acts as a viroporin, 
promoting viral uncoating within endosomes and stimulating 
the activation of the NLRP3 inflammasome (164). Nlrp3−/− and 
Casp1−/− mice were more susceptible to influenza infection, with 
decreased neutrophil and monocyte recruitment and an associ-
ated reduction in cytokine and chemokine production (165). 
This did not, however, translate into an effect on induction of the 
adaptive immune response. Ichinohe et al. expanded upon this 
and found that ASC and caspase-1, but not NLRP3, were required 
for the induction of CD4+ and CD8+ T cell responses, mucosal 
IgA secretion and systemic IgG responses (166). Influenza has 
therefore evolved several mechanisms to evade the activation of 
the NLRP3 inflammasome. PB1-F2 translocates into the inner 
membrane space of the mitochondria, acting to decrease the 
membrane potential and trigger mitochondria disintegration, 
which blocks formation of the inflammasome. Partial deletion of 
the amino-terminal RNA-binding domain of NS1 from influenza 
A rescues the production of IL-1β and IL-18 during infection, 
suggesting that this domain antagonizes the activation of caspase 
1 (167). Intriguingly, Goritzka et al. recently showed that while 
early lung infiltration of immune cells and levels of proinflam-
matory mediators were abrogated in Myd88/Trif/Mavs−/− mice 
(which lack TLR, RLR, and IL-1R signaling), there was no sub-
sequent effect upon the induction of RSV-specific CD8+ T cells 
(168). This implies that caspase-1 and TLR7 are essential to the 
development of adaptive immune responses to influenza virus, 
while the RIG-I pathway is more important in RSV but that 
redundant downstream pathways exist to induce cell-mediated 
immunity even in its absence.
Production of Innate IFNs by DCs and AMs
As discussed earlier, the pDC subset, which express TLRs at a 
high level, is known to be a potent producer of type I IFNs crucial 
to antiviral defense, and as such both RSV and influenza have 
developed mechanisms, such as NS directed antagonism to 
subvert this immunity (169, 170). This allows the viruses to act 
upon pDC directed immunity; during the acute phase of infec-
tion, patients hospitalized with H1N1 during the 2009 pandemic 
showed depletion of pDCs, as well as myeloid DCs (mDCs), 
with pDC counts remaining persistently low for up to 16 weeks 
(171). The consequences of this are seen in mouse models, which 
indicate that pDC depletion reduces influenza virus-specific 
serum antibodies during convalescence (172, 173). The engage-
ment of pDCs in influenza infection, particularly involving TLR7 
stimulation, leads not only to induction of type 1 IFNs, Th1 and 
cytotoxic responses, but also enhances B cell expansion and dif-
ferentiation into CD27high plasmablasts (174). However, it is clear 
that pDCs are not essential for the effective induction of CD8+ 
T cell responses or viral clearance (175), and may contribute to 
immune pathology (176).
Research into the effect of RSV upon pDCs has revealed a 
contradictory picture of immunity; work in mice has indicated 
that RSV infection inhibits the ability of lung resident pDCs to 
respond to TLR activation, reducing IFNα, IL-6, TNF-α, CCL2, 
CCL3, and CCL4 production, and impairing antigen presentation 
to T cells (169). This is supported by work in human cord blood 
derived pDCs exposed to RSV infection, which show reduced 
IFNα production (151). Conversely, human peripheral pDCs are 
capable of producing IFNα upon in vitro stimulation with RSV 
(177). While depletion of pDC, in the lungs of mice, affected 
IFNα levels following influenza, this was not the case with RSV 
(178), suggesting that pDCs play a less important role in type 1 
IFN production during RSV infection than in influenza.
Previous murine studies have implicated AMs, rather than 
DCs, as major producers of IFNα following RSV infection (172). 
Monocyte-derived AMs, which make up 95% of all leukocytes 
found in the airways, are important in antiviral defense, especially 
within the lower respiratory tract and orchestrate RSV immunity 
through type I IFN production (173). However, type I IFN defi-
cient murine AMs are still capable of controlling RSV replication 
(179), suggesting that this may not be their sole function. In con-
cert with studies which throw light onto the involvement of TLR 
signaling in RSV immunity, these results illustrate the difficulty 
in extrapolating from mouse models of infection to humans and 
indicate that peripheral and lung derived pDCs may differ mark-
edly in their function and response to the same viral pathogens.
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iLCs at the interface with Adaptive 
immunity
Innate lymphoid cells are a recently described family of effector 
cells which bridge innate and adaptive immune systems as well 
as having a crucial role in mucosal immunity. The prototypic 
group 1 ILC members, the natural killer (NK) cells, are the only 
currently known cytotoxic cells within the group and there is 
accumulating evidence that they have a role in antiviral immunity 
within the lung. These cells, which develop under the influence of 
IL-15 released by virally infected bronchial epithelial cells, clearly 
must achieve a delicate balance in influenza and RSV infection. 
Numerous studies have highlighted the role NK  cells play in 
both viral clearance and in the exacerbation of virus-induced 
lung pathology. Mouse models of influenza infection have 
shown that the presence of NKp46+ cells are important in the 
control of infection (180), with the peak of the antiviral response 
governed by NK cells displaying an activated phenotype. Human 
studies have also demonstrated that severe influenza infection is 
associated with diminished frequencies of circulatory NK  cells 
(181, 182). Welliver et  al. found extremely low levels of CD8+ 
T cells and NK cells within pulmonary tissues taken from infants 
with fatal RSV and influenza LRTI (183). Indeed, these infections 
were characterized by uncontrolled viral replication in individu-
als with an inadequate NK response, possibly suggesting a vital 
antiviral role for NK cells within respiratory tissues. Furthermore, 
a clue to the lethality of H5N1 influenza strains may be found 
in their avoidance of NK cell control. The HA protein of human 
and swine influenza binds to 2,6-linked sialic acid residues on the 
NK cell receptor, inducing NKp46-mediated killing, while H5N1 
(which binds preferentially to 2,3-linked residues), only initiates 
targeted cell death during human infection following activation 
of both NKp46 and NKG2D (184, 185). This impaired NK cell 
activation may help to explain the differential pathogenicity seen 
in the human and avian strains.
With both viruses, NK  cell-derived IFNγ has an important 
function in the protective response, although the signaling 
pathways are not yet clearly understood. In the case of RSV, 
NK cell depleted mice have been found to produce lower levels 
of IFNγ, with early IFNγ release promoting the development 
of a Th1 type response. Ordinarily this suppresses production 
of IL-25, which can drive the development of a Th2 polarized 
response, characterized by IL-4, IL-13 and mucus production 
(186). During influenza infection NK cell-derived IFNγ is also 
required for optimal cytotoxic T  lymphocyte (CTL) function 
and recall responses are augmented by NK cell IFNγ production 
(187). It is therefore unsurprising that both viruses have devel-
oped methods of subverting the NK response, with the G protein 
of RSV displaying a capacity for CX3C chemokine mimicry and 
acting as an antagonist to inhibit the trafficking of CX3CR1+ 
NK  cells (188). Influenza virus meanwhile, affects killer cell 
immunoglobulin-like receptors (KIR)/HLA-C interactions, 
increasing the binding of inhibitory receptors KIR2DL1 and the 
leukocyte Ig-like receptor, which act to inhibit NK cell function 
(189). The immunopathogenic effects of NK  cell accumulation 
and IFNγ release within delicate lung tissues are well known 
in both influenza and RSV infection and may go some way to 
explaining the increased survival and lowered morbidity seen 
in NK cell depleted mice infected with influenza (190). This is 
echoed by a reduction in ALI and morbidity (191) observed in 
NK cell depleted mice infected with RSV.
Apart from ILC1s, increasing evidence indicates that the 
other predominant innate effectors involved in respiratory viral 
infections are the ILC2s. Recent work in mouse models has dem-
onstrated that during the early stages of RSV infection the IL-13 
producing ILC2 subset are activated (192). If this finding is emu-
lated in humans, it may be one mechanism by which type 2 immu-
nopathology is promoted in some individuals. The dysregulation 
of the antiviral immune response can also be seen in influenza 
infection, in which IL-33 driven secretion of IL-13 by ILC2 cells 
contributes to airway hyperactivity and may exacerbate disease in 
asthmatic individuals (193). ILC2s are also the primary source of 
IL-5, another type 2 cytokine induced by IL-33 secretion, which 
has been shown to promote the accumulation of eosinophils and 
the exacerbation of disease in influenza infected lungs of mice 
(194), and these lung resident ILC2s contribute to the induction 
of an immunopathogenic type 2 response in RSV and influenza 
infections. This picture is somewhat complicated by emerging 
evidence that ILC subsets exhibit plasticity depending upon the 
inflammatory milieu. ILC3 cells are known to differentiate into 
ILC1 cells (and vice versa), and TLR2 promotes the production 
of IL-5 and IL-13 by ILC3 cells, suggesting that they are capable 
of differentiating into ILC2 cells. The ILC3 subset, which express 
retinoid-related orphan receptor γt and produce IL-17A/F and 
IL-22 has not been previously implicated in antiviral responses. 
However, work by Stier et al. has found that during RSV infec-
tion, reduced numbers of antiviral IFN-γ+ ILC1 and increased 
numbers of pathogenic IL-5+ and IL-13+ ILC2 and IL-17A+ ILC3 
accumulate in the lungs of STAT1-deficient mice (195). This raises 
the possibility that the inflammatory ILC3 subset may play a role 
in virally induced lung pathology. Alongside the newly described 
ILC regulatory subset, it remains to be seen, however, whether 
ILC3 cells have a functional role in the antiviral response.
The inflammatory milieu within the lungs during viral infec-
tions is heavily composed of neutrophils. These short-lived, 
terminally differentiated, phagocytic cells have been implicated 
in the early response to RSV, especially in infants which go on to 
develop bronchiolitis (196). Their recruitment to sites of infec-
tion within the mucosal tissues is associated with viral killing by 
oxygen dependent and independent mechanisms. In addition to 
this secretion of antimicrobial products through degranulation, 
activated neutrophils also release neutrophil extracellular traps 
(NETs), which consist of chromatin and granule proteins such as 
elastase. Neutrophil-derived elastase and chemoattactants such 
as IL-8 are elevated during initial RSV infection, and neutrophils 
are capable of ameliorating disease during influenza infection 
(197, 198). During the course of infection with both viruses an 
influx of neutrophils can stimulate antiviral IFNγ release by CD8+ 
T cells (199, 200). In mouse models of influenza infection, admin-
istration of the mAb 1A8 (which specifically targets the Ly6G 
antigen expressed by neutrophils), enhances viral replication 
and exacerbates pulmonary inflammation, edema, and respira-
tory dysfunction (201). Depletion of neutrophils with 1A8 also 
impairs the cytotoxic function and cytokine release of influenza 
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specific pulmonary CD8+ T cells (202), and can lead to increased 
susceptibility to lethal challenge with virulent influenza strains 
(198). However, contradictory evidence suggests that excessive 
infiltration of neutrophils into the airways is associated with a 
fatal outcome in H7N9 and H1N1 infected patients, with NETs 
playing a key role in influenza induced lung damage (203). The 
importance of neutrophil infiltration and formation of NETs 
in ALI has also been observed in mouse models of sublethal 
influenza challenge. Following administration of 1A8 mAb, mice 
exposed to H1N1 on a PR8 backbone strain demonstrated milder 
lung pathology than macrophage depleted mice (204). Research 
by Brandes et al. suggests that neutrophil infiltration establishes 
a damaging feed-forward loop which is dependent upon the 
viral strain and inoculating dose (205), which may go some 
way to explaining the discrepancies observed in the pathogenic 
role neutrophils play during influenza infection. It appears that 
while recruitment of these destructive cells to the delicate tissue 
of the lung may be crucial in early clearance of viral particles, 
their proinflammatory nature can also cause substantial immune 
pathology.
Antigen Presentation and induction of 
Proinflammatory Cytokines by DCs
Dendritic cells play a crucial role in linking the innate and 
adaptive immune systems, especially at mucosal surfaces. The 
majority of immature DCs fulfill a sentinel function in the 
periphery, including the respiratory system. Here, they may 
remain for up to two weeks before leaving tissues via the lymphat-
ics, although the turnover of DCs in the mucosa is much faster. 
Engagement of PRRs expressed by DCs leads to the upregulation 
of costimulatory molecules, and the generation of proinflam-
matory cytokines, such as IL-6, IL-12, and TNF, which trigger 
a maturation program determining how a naive T cell responds 
to antigen stimulation. The wide range of pulmonary DC subsets 
fulfill distinct, occasionally overlapping functions, influencing 
viral clearance from the lung and induction of T cell responses. 
Following PRR stimulation, DCs downregulate the expression 
of tissue retaining chemokine receptors, CXCR1, CCR1, CCR2, 
and CCR5, and upregulate CCR7 and CD11c, allowing the DC 
to home to secondary lymphoid organs. Within the lymph node 
or spleen the mature DC, which has massively upregulated the 
expression of both peptide-loaded major histocompatibility 
complex (MHC) and costimulatory molecules at the cell surface, 
is capable presenting antigen to cognate T  cells. Murine lung 
DCs can be divided into CD103+ conventional DCs (cDCs) and 
CD11b+ cDCs (in humans these correspond, respectively, to the 
CD141+ and CD1c+ DC subsets), and plasmacytoid DCs (pDCs). 
Monocyte-derived DCs are also generated in the lung during 
inflammatory episodes.
Influenza and RSV infection have both been reported to cause 
CD103+ cDCs to migrate from the intraepithelial basement layer 
to draining mediastinal lymph nodes for antigen presentation 
to naive T cells (175, 206). However, severe influenza infection 
particularly leads to lymph node accumulation of CD11b+ 
cDCs in the lymph nodes, with these DC subsets dominating 
antigen presentation at the peak of infection (207). As priming 
during early infection is characterized by a more even balance of 
CD11b+ and CD103+, it is unclear whether severity of infection, 
inoculating dose or temporal kinetics govern the subsets acti-
vated. In the context of viral immunity it is important to note that 
these DCs tend to differ in their antigen presentation. CD11b+ 
cDCs readily present viral antigens to CD4+ T cells through MHC 
class II, promoting both Th2 and Th17 responses. CD103+ cDCs, 
meanwhile are capable of biasing toward a Th1 response, but also 
specialize in the cross-presentation of antigen through MHC 
class I pathways, driving CD8+ T  cell priming. This is further 
complicated by studies indicating that differential expression 
of CD24 by CD103+ DCs and CD11b+ DCs lead to preferential 
induction of effector and central memory CD8+ T cells, respec-
tively (208). Bearing this in mind, it is unsurprising that depletion 
of CD11c+ cDCs results in the impaired development of influenza 
virus-specific CD8+ T cells in the mouse model (175, 209),.
Significantly, studies in neonatal mice have described a fun-
damental shift in the balance of cDC subsets in early life. While 
both CD103+ and CD11b+ cDCs are substantially less effective 
in infants than adults, a functionally limited CD103+ population 
dominates the response in favor of a diminished CD11b+ cDC 
subset in early life (210). In mice, this shift in cDC subsets influ-
ences the CD8+ T cell epitope hierarchy during RSV infection, 
dramatically changing the immunodominant epitopes between 
infancy and adulthood (210, 211). Recent work by Ruckwardt 
et al. suggests in the neonatal mouse model that both RSV and 
influenza infection lead to the production of a distinct CD103low 
population which predominates over CD103high in early life. 
These express lower levels of lineage-defining markers and 
costimulatory molecules, as well as more limited antigen uptake 
and processing capabilities (211). This highlights the complex 
and subtle changes undergone by the immune system at different 
ages, confounding our understanding of antiviral immunity in 
patients.
DiFFeReNTiAL iNDuCTiON OF LONG-
TeRM HuMORAL iMMuNiTY BY 
iNFLueNZA AND RSv
Natural infection by influenza is known to induce long-lived 
high affinity antibodies that are associated with complete 
protection from symptomatic infection for many years (212). 
However, the defining characteristic of influenza vaccination is 
the requirement for reformulation on a regular basis to match 
predominant circulating strains. This is due to the majority of 
human antibodies induced by influenza being directed toward 
the immunodominant globular head domain of HA. Following 
infection, high levels of strain-specific anti-HA antibodies confer 
long-lasting protection that can endure for many years, but rapid 
accumulation of mutations in the globular HA head leads to 
antigenic escape. Recent work to develop a cross-strain protective 
vaccine has therefore focused on inducing antibodies against the 
more conserved HA stalk. Mouse studies have demonstrated that 
sequential exposure to divergent influenza strains can trigger the 
production of broadly neutralizing anti-stalk antibodies (213). 
In humans, infection with pH1N1 boosted the production of 
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HA stalk antibodies and these neutralizing antibodies could in 
principle be replicated by vaccination (214). However, while neu-
tralizing antibodies are understood to correlate with protection 
against influenza infection, it has been suggested that heterosub-
typic stalk-binding mAbs may be less effective and display limited 
activity against cell-bound viruses (215). Nevertheless, conflicting 
evidence has revealed that not only may these antibodies actually 
outperform conventional neutralizing antibodies within a more 
physiologically relevant polyclonal condition (216), but also that 
in vivo these antibodies are able to activate antibody-dependent 
cellular cytotoxicity which correlates with enhanced antiviral 
protection (217).
Historically vaccine efforts against RSV have also focused on 
the induction of neutralizing antibody titers, and an association 
between systemic antibody levels and protection from severe dis-
ease has been shown both in hospitalized patients and in animal 
models (218). Indeed, the efficacy of the mAb palivizumab in 
reducing RSV-related hospitalization in high-risk infants proves 
the efficacy of serum IgG alone in preventing RSV LRTI (219). 
However, it has long been known that while higher levels of neu-
tralizing antibody and F protein-specific IgG do correlate with 
protection from severe disease, it is still possible to experimentally 
re-infect adults with RSV regardless of their systemic antibody 
levels (11). This contrasts with influenza, where re-challenge 
after an interval of as much as 7 years fails to induce any viral 
replication or symptoms (212), and pH1N1 antibodies are long-
lasting (220). This has led to difficulty in identifying a threshold 
of protective titers for anti-RSV antibodies. Furthermore, levels 
of antibody show a precipitous decline post-infection and do not 
provide incremental protection during subsequent RSV seasons 
(221).
As respiratory viruses, both RSV and influenza are capable of 
inducing mucosal IgA, which acts as first-line antiviral defense. 
Mouse models have confirmed that these antibodies are secreted 
rapidly in the upper airways following primary infection with 
RSV (222), and in both viruses secretory IgA (sIgA) has been 
shown to confer protective immunity in mice (222–224). In 
humans the role of sIgA in protection is relatively poorly under-
stood. However, recent RSV challenge studies have revealed that, 
while serum antibody does not significantly affect the likelihood 
of infection, nasal anti-RSV and anti-F protein IgA titers are sig-
nificantly higher in individuals who are resistant to experimental 
challenge (225). This is supported by findings by Bagga et  al. 
confirming that pre-existing nasal IgA is a predictor of lower 
infectivity and viral replication, although in this model, serum 
neutralizing antibody titers played a greater role in predicting 
immunity (226).
Antibody producing B cells can be generated in a T cell depend-
ent or independent manner. The majority of IgA+ memory B cells 
(MBC) and long-lived IgA+ plasma cells develop within the ger-
minal centers (GC) of peripheral lymphoid organs, undergoing 
affinity maturation and somatic hypermutation, predominantly 
requiring T-cell help via CD40L and transforming growth factor 
(TGF) β1, although T-cell independent B-cell class switching has 
been observed in the GC, mediated by follicular DCs (fDC). DCs 
are derived from mesenchymal rather than hematopoietic origin, 
and unlike pDCs and mDCs they do not express MHC molecules 
at the cell surface; instead antigens complexed to antibodies or 
complement are displayed at the cell surface for recognition by 
B lymphocytes. These antigen presenting cells (APCs) are a key 
component in the generation of long-lived MBC and plasma cells, 
but mature fDC networks are absent in early life, which may limit 
responses of T cell dependent ASCs. MBCs and plasma cells have 
distinct phenotypic characteristics, which may be impacted by 
early life experiences with enduring consequences upon immune 
responses. Human challenge models have demonstrated that 
while IgG+ MBC frequencies increase following both RSV and 
influenza infection these cells did not influence the outcome 
of viral challenge (225). There was however a profound defect 
in the induction of RSV- and F-specific IgA-producing MBCs 
which showed no detectable increase in frequency following 
RSV infection (225). This can be contrasted with individuals 
naturally infected during the 1918 influenza pandemic, who were 
found to have functional strain specific MBCs circulating up to 
70  years following exposure (227) with long-lived plasma cells 
producing high affinity antibodies against not only 1918 strains, 
but also contemporary pH1N1 from 2009 (228).
Antigen-specific IgG and IgA producing MBCs also develop 
at extrafollicular mucosal sites in a T cell dependent or independ-
ent manner, involving B cell activating factor of the TNF family 
(BAFF) and a proliferation-inducing ligand (APRIL), which in 
influenza infection leads to protection against reinfection with 
similar strains (229). BAFF protein expression has been found in 
the upper airways of children with influenza virus, as well as in 
the lower airways of infants with severe RSV bronchiolitis (230). 
However, recent work in the closely related BRSV has suggested 
that the SH protein not only inhibits NF-κB expression in APCs 
(231), but also blocks phosphorylation of STAT1 thereby inhibit-
ing BAFF expression and potentially interfering with induction 
of B cell responses. Infection of APCs with an SH deletion mutant 
led to increased production of BAFF and APRIL. It remains to 
be seen whether this action of the human RSV SH protein may 
contribute to the peculiar defect in MBC induction seen in RSV, 
but not influenza.
GeNeRATiNG eFFeCTive T CeLL  
HeLP iN iNFLueNZA
Animal models have clearly shown that both CD4+ and CD8+ 
T  cells are essential for effective resolution of viral infection 
and protective memory. Influenza vaccination strategies may 
therefore be improved by targeting conserved regions of HA 
and NA antigens for presentation by MHC molecules to expand 
the CD4+ T cell repertoire. This is an attractive strategy as CD4+ 
T cells are capable of supporting both humoral responses and 
enhancing CD8+ T cell immunity to generate high affinity and 
cross-protective responses. The predominant CD4+ population 
capable of inducing the generation of high-affinity, class-switched 
antibodies are the T follicular helper (TfH) cells which reside 
within the GC. These cells are involved in the production of IL-2, 
IL-4, IL-10, TGFβ, and IL-21, which promotes the generation 
of plasma cells and MBCs (232). TGFβ and IL-21 in particular, 
have been found to promote class-switching and stimulate the 
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generation of IgA+ plasmablasts (233). These cytokines also 
act to downregulate CXCR5 and upregulate CCR10 on plas-
mablasts, enhancing migration toward local mucosa. TfH cells 
expressing CXCR5, programmed cell death protein 1 (PD-1), 
inducible costimulator (ICOS), CD28, CD40L, the adaptor 
protein SAP, and the B  cell lymphoma 6 (Bcl-6) transcription 
factor are abundant in the nasopharynx-associated lymphoid 
tissues during early childhood. Stimulation by live attenuated 
influenza vaccine induces a marked increase in TfH frequency 
which correlates with anti-HA IgA IgG and IgM antibodies in 
human tonsillar cells (234). Work by Leon et  al. in mice has 
furthered our understanding of the GC TfH response to viral 
antigens, suggesting that FoxP3+ Tregs play a critical role in the 
differentiation of influenza-specific TfH cells by regulating the 
availability of suppressive IL-2 in vivo (235). Miyauchi et al. has 
also posited that mice deficient in Bcl-6, and consequently TfH 
cells, are capable of producing low affinity IgG2 neutralizing 
antibodies, which nevertheless provide protective immunity 
against lethal challenge with pathogenic H5N1 and pH1N1 
strains (236). It is possible, in this case, that the role of promot-
ing B cell proliferation and differentiation into plasma cells was 
assumed by IL-21 and IFNγ-secreting CXCR3+CD4+ Th1 cells. 
The existence of a circulating compartment of TfH cells within 
the periphery has also been recently demonstrated in humans. 
This ICOS+ PD-1+ CXCR3+ population correlates with the 
generation of high-avidity antibodies following influenza vac-
cination (237, 238).
There is a paucity of work demonstrating the role of CD4+ 
T cells in human RSV. The first work exploring the impact of RSV 
upon TfH suggested that this virus is capable of upregulating 
expression of programed death ligand 1 (PD-L1) on murine DCs 
and B cells to decrease TfH production of IL-21 and expression 
of IL-21R (239). It is already known from coculture experiments 
that blocking PD-L1 on RSV-infected bronchial epithelial cells 
enhances effector-memory and terminally differentiated CD8+ 
T cell secretion of IFNγ, and granzyme B, enhancing viral clear-
ance (240). It is currently not known whether Tregs affect TfH dif-
ferentiation in response to RSV, with the impact of Tregs during 
an RSV infection related to their recruitment of activated CTLs 
into the lungs, increasing viral clearance (241). RSV may also act 
to inhibit Treg differentiation, stimulating a pathogenic Th17/
Th2 response (242, 243). If defects in CD4+ T cell help of B cells, 
such as a dysregulated PD-L1/IL-21 axis or failure to promote 
class switching to IgA in the secondary lymphoid tissues, can be 
demonstrated in human RSV infection, this may provide fresh 
clues regarding mechanisms by which this virus modulates the 
protective adaptive response.
iMPAiReD CeLL-MeDiATeD iMMuNiTY  
iN HuMAN RSv
The protective and pathogenic effects of T  cells in respiratory 
virus infections have been extensively reviewed elsewhere 
(244–247). Mouse models have shown that both CD4+ and CD8+ 
T  cells mediate RSV clearance (248), and studies in hospital-
ized infants have demonstrated a robust antigen-specific CD8+ 
T cell response peaking at convalescence (249, 250). In addition, 
heterosubtypic immunity against influenza in mice is promoted 
by crossreactive CD8+ T cells (251), while antibody production 
is impaired in T cell deficient mice (252). In humans, both CD4+ 
and CD8+ influenza specific T cells have been shown to correlate 
with reduced disease severity in experimental challenge and 
natural infection (129, 253).
However, in human RSV, impairment in T cell function has 
been implicated in susceptibility to recurrent infection. For 
example, population-based studies have shown an association 
between reduction in T cell numbers and function and suscep-
tibility to more severe disease. This is perhaps more obvious in 
older adults, where an age-related decreases in the numbers of 
RSV-specific T  cells and ratio of CD8+/CD4+ memory T  cells 
expressing IFNγ is associated with waning immunity observed in 
elderly adults (254–256). However, confounding difficulties with 
confounders in natural infection studies have meant that there are 
also studies which do not show impaired CD8+ T cells activation 
in response to RSV infection in the elderly (257).
Human challenge studies of young adults have more directly 
demonstrated the limited polyfunctionality of circulating 
RSV-specific CD8+ T  cells compared to influenza-specific 
CD8+ T  cells from the same individuals (128). During RSV 
infection cDCs and pDCS are capable of migrating to draining 
lymph nodes bearing antigens from the lung, but these cells 
have proven poor inducers of CD4+ T cell proliferation (177). 
In vitro studies have also suggested that RSV infection causes 
suboptimal DC activation and that these DCs are defective 
in antigen presentation via the immune synapse (258). Given 
that primary expansion, CTL activity and effective long-term 
memory of antiviral CD8+ T cells are all optimally dependent 
upon CD4+ T cell help, this may suggest a mechanism for RSV 
impaired CD8+ T cell function as well as B cell memory. Indeed, 
in an in vitro coculture system, DCs pulsed with recombinant 
RSV NS1-deletion mutant resulted in an increased activation 
and proliferation of tissue homing CD103+ CD8+ T  cells and 
antiviral Th17  cells, suggesting an NS1-mediated mechanism 
of immune modulation being responsible for CD8+ T  cell 
impairment (259). RSV infection of DCs has also been shown 
to inhibit the production of proinflammatory cytokines, includ-
ing IFNγ (260). The result, it has been speculated, is suboptimal 
signaling to T cells and therefore failure to optimally stimulate 
a full program of differentiation for the generation of long-lived 
polyfunctional T cells.
In mouse models of influenza Tem cells proliferate in the lungs 
contributing to heterosubtypic immunity (261, 262). However, 
Jozwik et al. did find that local virus-specific CD8+ T resident 
memory (Trm) cells in the airway (that express the canonical 
markers CD103 and CD69) correlated significantly with reduced 
RSV disease severity, suggesting that while T cell functionality 
might be impaired, their presence at the site of infection could 
still lead to improved outcome (128). The role of Trm cells in 
immunity against respiratory viruses has only recently begun to 
be unraveled, with these cells differentiating in the lymph node 
following antigen presentation by CD103+ DCs. Given that both 
RSV and influenza infection promote CD103low DCs in early life, 
it is tempting to speculate that this represents an attempt by the 
TABLe 1 | Comparative immunity against influenza and respiratory syncytial virus 
(RSV).
influenza RSv




Recurrent symptomatic infection 
throughout life
Virology Highly variable surface 
glycoproteins
Segmented genome
Major surface target F protein 
highly conserved
Non-segmented genome























CX3C chemokine mimicry 
dysregulates inflammation
Antibodies Protective and 
long-lasting
Protective but short-lived
B cells Robust IgG+ and IgA+ 
MBCs
IgG+ MBCs
Poor IgA+ MBC response
Inhibition of BAFF?
T cells Th1 and CD8+ 
dominated
Highly polyfunctional
Th2/Th17 bias in early life
Poor polyfunctionality
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viruses to subvert Trm production. Recent work by Zens et al. 
has also shed light upon the inefficient generation of Trm cells 
observed in early life (263). It appears that the reduced genera-
tion of Trm may be a factor intrinsic to infancy, as mouse models 
of influenza infection and vaccination demonstrate ineffective 
generation of lung Trms and promotion of long term memory, 
despite the generation of CD4+ and CD8+ effector T cells capable 
of viral clearance (263). In contrast to immunity in adults, in 
infants the distinct transcriptional profile of these lung-homing 
T cells favors enhanced T-bet expression and reduced expression 
of the survival factor CD127, leading to pathogen clearance by 
terminally differentiated T  cells. Furthermore, it is clear from 
influenza mouse models that CD4+ T cell help is required for the 
promotion of CD103+ CD8+ Trm cells (264) and so both play 
an important part in the induction of heterosubtypic immunity 
(265). Interestingly, unlike most other tissues where Trm cells 
have been investigated, lung Trm cells are not persistent and 
undergo attrition over time (265, 266). In view of the work 
by Jozwik et al. this suggests that while Trm can be important 
in the early clearance of viruses from the lung, RSV-specific 
impairment of T  cell functionality contributes more rapidly 
to the downregulation of protective immunity, compared with 
influenza.
It remains to be seen whether stimulation of Trm cells by 
influenza or RSV vaccination can enhance protection but if 
indeed they can, a careful balance is likely to be required. Data 
from healthy young adults in experimental challenge and natural 
infection studies as well as in infants with severe RSV and influ-
enza LRTI all suggest that lower CD8+ T cell numbers may be 
associated with more severe disease (183). H owever, induction 
of T cell immunity in the delicate mucosal structures of the lung 
has also been associated with greater severity of disease, with 
a higher frequency of activated T  cells in both experimentally 
infected mice (248, 267) and RSV-infected adults who required 
hospitalization (257). This dysregulation of the immune system 
may also be seen in influenza infection with an increased release 
of proinflammatory cytokines. Thus, cell-mediated immunity is 
critical in clearing viral infection and coordinating the adaptive 
immune response as a whole. However, the exact role of each 
subset, their anatomical location and how they can be induced 
and maintained at optimum levels must be better understood 
before harnessing them to improve protection.
CONCLuSiON
It has long been recognized that influenza and RSV infection 
lead to highly distinct clinical and immunologic outcomes in 
humans. While the long-lived antibody and cell-mediated 
protection conferred by influenza infection is the prototype 
of a complete and robust antiviral response, immunity against 
RSV is poor in all settings and unable to fully protect against 
recurrent symptomatic infection even with an identical strain. 
It is increasingly clear from natural infection and human chal-
lenge studies that the immediate reason for this is impairment in 
quantity, quality and durability of antibodies, B cells and T cells. 
However, the underlying mechanisms leading to this remain 
poorly understood. It seems likely from the wealth of in vitro 
and animal data that both influenza and RSV subvert innate 
immunity in order to establish infection (Table  1). However, 
RSV additionally impairs long-term memory generation. The 
relative contribution of mechanisms such as alteration of the 
inflammatory environment, IFN inhibition, and impaired anti-
gen presentation is still unclear. By further understanding of how 
influenza induces robust immunity whilst RSV evades it, a more 
general understanding of the critical components of an effective 
immune response is now coming through but many knowledge 
gaps remain. Development of novel vaccination strategies are 
likely to require these insights so that immunogenicity can be 
optimized through avoiding or overcoming pathogen-induced 
immunomodulatory mechanisms and thus successfully elicit 
long-term protective immunity.
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